Dr Singh is working on several multi-disciplinary research projects at UKZN that involves the synthesis, biological testing against diabetes, cancer and bacterial infections and molecular modelling studies. He was a recipient of prestigious DST-NRF Free-standing Post-doctoral fellowship and featured as one of the emerging researchers in South Africa by the NRF. He has also been recipient of top university and College publisher award on several occasions. For his contributions in science, the NRF has rated him an established researcher with the C2 rating in 2019. Since his appointment at UKZN (2014), he has successfully graduated 6 PhDs and 5 Master students. He also has published around 100 publications in peer-reviewed journals of international repute.
Dr Singh’s group is working on several multi-disciplinary research projects involving the synthesis, molecular modelling and biological evaluation of heterocyclic scaffolds. Predominantly, we are using[2+2], [3+2] and [4+2] cycloaddition modes to synthesize heterocyclic pharmacophoric assemblies of different ring sizes. In parallel, They are also using various molecular modeling techniques such as molecular docking, molecular dynamics, QSPR and density functional theory (DFT) calculations to complement our experimental studies.
Dr Singh’s group is currently using the molecular hybridization and cycloaddition methodologies to prepare a variety of heterocyclic scaffolds including pyrimidinones, beta-lactams, thiadiazolo-pyrimidinones, caumarin-1,2,3-triazoles, coumarin-oxadiazole, pyrazoles, chalcones, alkenes, thiadiazole-thiazolidinoneconjugates. Some of the synthesized compounds such as pyrimidinones, tetra substituted alkenes, coumarins and carbapenam chalcones, tested in vitro against breast (MCF-7, MDA-MB-231), lung (A-549), colon (Caco2), hepatocellular (HepG2) and cervical (HeLa) cancer cell lines have shown promising activities. Additionally, we are also exploring the antidiabetic and antimicrobial potential of thiazolidone-and quinoline-based heterocycles. We are also using molecular docking simulations to determine the binding modes of potent compounds in the active sites of their receptors.